IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 3.5% - Should You Sell?

Key Points

• OptimUM‑02 reported positive topline results — the darovasertib + crizotinib combination met the trial's primary endpoint with median PFS 6.9 vs 3.1 months (HR 0.42), supporting potential regulatory filings and commercial opportunity in uveal melanoma.
• The stock traded down about 3.5% intraday to roughly $31.65 on lighter volume, even as several firms raised targets (Wedbush $58, Guggenheim $54, Wells $48) and the consensus rating sits at "Moderate Buy" with a $50.44 average price target—implying notable upside vs. the current price.
• Significant risks remain: regulatory approval, safety, and payer acceptance are not guaranteed in a small specialty market, and the company is still unprofitable (negative EPS), which could limit upside despite encouraging trial data.

IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) was down 3.5% during mid-day trading on Tuesday . The company traded as low as $30.71 and last traded at $31.6550. Approximately 755,330 shares changed hands during mid-day trading, a decline of 29% from the average daily volume of 1,069,156 shares. The stock had previously closed at $32.82.

Key Stories Impacting IDEAYA Biosciences

Here are the key news stories impacting IDEAYA Biosciences this week:

• Positive Sentiment: OptimUM‑02 reported a statistically significant improvement in median progression‑free survival (BICR): 6.9 months for the darovasertib combination vs 3.1 months for investigational control (HR 0.42), meeting the trial's primary endpoint — a clear clinical readout that supports potential regulatory filings and commercial opportunity in a high‑unmet‑need indication. IDEAYA and Servier announce positive topline results (PR Newswire)
• Positive Sentiment: Wide media coverage highlights the trial success and investor enthusiasm (reports of share moves and analyst attention), amplifying sentiment and trading volume following the announcement. Ideaya stock jumps on eye cancer trial results (Barron's)
• Positive Sentiment: Wedbush raised its price target to $58 and kept an "outperform" rating — the highest of the three published raises — implying meaningful upside vs. the current price and signaling increased sell‑side conviction. Wedbush raises price target to $58 (The Fly)Coverage summary (Benzinga)
• Positive Sentiment: Guggenheim raised its target to $54 and reiterated a "buy" rating, adding institutional validation of the trial data's commercial implications. Guggenheim raises target to $54 (Benzinga)
• Positive Sentiment: Wells Fargo raised its target to $48 and moved to "overweight," reflecting broader analyst upgrades that can support continued bullish momentum and higher targets in the near term. Wells Fargo raises target to $48 (Benzinga)
• Neutral Sentiment: Company filed detailed topline results and management provided transcripts/slides for investors; these materials help analysts refine models but require regulatory and safety review to translate into approvals. OptimUM‑02 topline results slides/transcript (Seeking Alpha)
• Negative Sentiment: Analysts and commentators caution that regulatory approval and commercial rollout are not guaranteed — uveal melanoma is a small, specialized market and further safety, regulatory review, and payer acceptance remain risks that could limit upside. Approval not a formality — analysis (Seeking Alpha)

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on IDYA shares. Wall Street Zen downgraded shares of IDEAYA Biosciences from a "buy" rating to a "sell" rating in a research report on Saturday, February 21st. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of IDEAYA Biosciences in a research note on Wednesday, February 18th. Wells Fargo & Company increased their price objective on IDEAYA Biosciences from $44.00 to $48.00 and gave the stock an "overweight" rating in a report on Tuesday. Royal Bank Of Canada boosted their target price on IDEAYA Biosciences from $49.00 to $53.00 and gave the company an "outperform" rating in a research note on Tuesday. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of IDEAYA Biosciences in a research report on Thursday, January 22nd. Fifteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $50.44.

IDEAYA Biosciences Stock Performance

The company's 50 day moving average price is $32.41 and its 200 day moving average price is $32.58. The company has a market cap of $2.81 billion, a price-to-earnings ratio of -24.39 and a beta of 0.02.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its earnings results on Tuesday, February 17th. The company reported ($0.94) EPS for the quarter, topping the consensus estimate of ($1.03) by $0.09. The business had revenue of $10.88 million for the quarter, compared to analyst estimates of $5.95 million. The company's quarterly revenue was up 55.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.49) earnings per share. On average, equities research analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Jeffrey Stein purchased 50,000 shares of the company's stock in a transaction dated Monday, March 2nd. The shares were bought at an average price of $32.96 per share, with a total value of $1,648,000.00. Following the completion of the transaction, the director directly owned 54,281 shares in the company, valued at $1,789,101.76. This trade represents a 1,167.95% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Farther Finance Advisors LLC boosted its holdings in IDEAYA Biosciences by 171.1% during the fourth quarter. Farther Finance Advisors LLC now owns 919 shares of the company's stock valued at $32,000 after acquiring an additional 580 shares during the period. Aster Capital Management DIFC Ltd bought a new position in shares of IDEAYA Biosciences in the third quarter worth about $38,000. ANTIPODES PARTNERS Ltd lifted its position in shares of IDEAYA Biosciences by 49.4% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company's stock worth $40,000 after purchasing an additional 380 shares during the last quarter. Abich Financial Wealth Management LLC acquired a new position in shares of IDEAYA Biosciences during the 3rd quarter worth about $58,000. Finally, Global Retirement Partners LLC bought a new stake in IDEAYA Biosciences during the 4th quarter valued at approximately $61,000. Institutional investors own 98.29% of the company's stock.

About IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA's pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA's approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.